ANI PHARMACEUTICALS, INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ANI PHARMACEUTICALS, INC (ANIP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -8.80% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2024 was -8.80%, a 519.05% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2023 was 2.10%.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was -0.50%.
- ANI PHARMACEUTICALS, INC effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was -0.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2024-12-31 | -8.80% 10-K · filed 2026-02-27 |
| 2023-12-31 | 2.10% 10-K · filed 2026-02-27 |
| 2022-12-31 | -0.50% 10-K · filed 2025-02-28 |
| 2021-12-31 | -0.80% 10-K · filed 2024-02-29 |
| 2020-12-31 | -3.50% 10-K · filed 2023-03-09 |
| 2019-12-31 | 9.10% 10-K · filed 2022-03-15 |
| 2018-12-31 | 0.00% 10-K · filed 2020-02-27 |
| 2017-12-31 | 0.50% 10-K · filed 2020-02-27 |
| 2015-12-31 | 0.10% 10-K · filed 2016-02-23 |
| 2014-12-31 | 0.00% 10-K · filed 2016-02-23 |
| 2013-12-31 | 245.90% 10-K · filed 2016-02-23 |
| 2012-12-31 | 17.70% 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |